A61P 3 - Drugs for disorders of the metabolism

Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
10/2001
10/25/2001	WO2001079156A1 Halogenated 2-amino-4, 5 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
10/25/2001	WO2001079153A1 Compounds, compositions and methods for preventing neurodegeneration in acute and chronic injuries in the central nervous system
10/25/2001	WO2001079150A1 New compounds, their preparation and use
10/25/2001	WO2001078781A2 Methods for prevention and treatment of gastrointestinal disorders
10/25/2001	WO2001078779A2 Antibody alpha4beta7 integrin and its use to treat inflammatory bowel disease
10/25/2001	WO2001078771A1 Method of preventing or treating diabetes
10/25/2001	WO2001078768A2 Targeted vaccine delivery systems
10/25/2001	WO2001078727A1 Topical formulations for the transdermal delivery of niacin and methods of treating hyperlipidemia
10/25/2001	WO2001078723A1 Compounds and methods
10/25/2001	WO2001078718A1 Methods of use of penicillamines for the treatment of conditions resulting from dna damage
10/25/2001	WO2001078709A2 Treatment of neurodegenerative disease
10/25/2001	WO2001078680A2 Pharmaceutical compositions comprising fluvastatin
10/25/2001	WO2001078675A1 Use of natural substances in the production of cosmetic preparations
10/25/2001	WO2001078534A2 Beta-glucan compositions for reducing hypercholesterolemia and controlling of postprandial blood glucose and insulin levels
10/25/2001	WO2001078533A2 Nutritional modules
10/25/2001	WO2001078532A1 Composition comprising free amino acids
10/25/2001	WO2001078529A2 Compositions and methods for improving vascular health
10/25/2001	WO2001056596A8 Use of lysosomal acid lipase for treating atherosclerosis and related diseases
10/25/2001	WO2001044246A8 Bicyclic inhibitors of glycogen synthase kinase 3
10/25/2001	WO2001034781A3 Lytic enzymes useful for treating fungal infections
10/25/2001	WO2001027113A3 PYRAZOLO `4,3-d! PYRIMIDINE DERIVATIVES
10/25/2001	WO2001025238A3 Heterocyclic compounds useful as inhibitors of tyrosine kinases
10/25/2001	WO2001022976A3 Combination of a statin and ex-vivo treated blood for treating artheroclerosis
10/25/2001	WO2001012790A3 Isomerase proteins
10/25/2001	WO2000064896A9 Polymorph of 5-[4-[2- (n-methyl-n-( 2-pyridyl)amino) ethoxy]benzyl] thiazolidine-2,4-dione, maleic acid salt
10/25/2001	WO2000047104A3 Antagonists of hmg1 for treating inflammatory conditions
10/25/2001	US20010034448 New compounds, their preparation and use
10/25/2001	US20010034371 Antidiabetic agents
10/25/2001	US20010034364 Isoprenoid pathway inhibitors for stimulating bone growth
10/25/2001	US20010034359 Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies
10/25/2001	US20010034348 Nitric oxide synthase inhibitor; nervous system disorders
10/25/2001	US20010034340 Hormone replacement therapy
10/25/2001	US20010034331 Isolated polypeptide
10/25/2001	US20010034051 For example: (2-(3-amino-4-nitrophenyl)amino)ethyl)(6-(2,4-dichlorophenyl-5-nitropyrazin -2-yl)-amine; antidiabetic, -carcingenic and ischemic agents; nervous and cardiovascular system disorders; immunotherapy; obesity; syndromes
10/25/2001	US20010033881 Composition of fructose, vitamin b complex and taurine; effectively and rapidly controlling the effects of excessive alcohol consumption
10/25/2001	DE10019062A1 Use of known and new 2-guanidino-4-aryl-quinazoline derivatives as NHE-3 inhibitors useful for the treatment of e.g. hypertension, thrombosis, cardiac ischemia, peripheral and CNS ischemia
10/25/2001	CA2747325A1 Albumin fusion proteins
10/25/2001	CA2407531A1 Imidazopyrimidine derivatives and triazolopyrimidine derivatives
10/25/2001	CA2406947A1 Methods for prevention and treatment of gastrointestinal disorders
10/25/2001	CA2406378A1 Targeted vaccine delivery systems
10/25/2001	CA2406245A1 Il-174 uses, compositions and methods
10/25/2001	CA2406220A1 Antibody alpha4beta7 integrin and its use to treat inflammatory bowel disease
10/25/2001	CA2405803A1 Compositions for reducing hypercholesterolemia and controlling of postprandial blood glucose and insulin levels
10/25/2001	CA2405709A1 Albumin fusion proteins
10/25/2001	CA2405701A1 Albumin fusion proteins
10/25/2001	CA2405563A1 Albumin fusion proteins
10/25/2001	CA2405557A1 Albumin fusion proteins
10/25/2001	CA2405550A1 Albumin fusion proteins
10/25/2001	CA2405525A1 Albumin fusion proteins
10/25/2001	CA2405451A1 Molecules associated with human reproduction
10/25/2001	CA2405377A1 Nutritional modules
10/25/2001	CA2404858A1 Treatment of neurodegenerative disease
10/25/2001	CA2403591A1 Pharmaceutical compositions comprising fluvastatin
10/25/2001	CA2402374A1 Processes for the preparation of thiazolidinedione derivatives and intermediates
10/24/2001	EP1148062A2 Sterol compositions from pulping soap
10/24/2001	EP1148054A1 Thyroid receptor ligands
10/24/2001	EP1148049A1 Crystalline R-(R,R)$-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- (phenylamino)carbonyl -1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
10/24/2001	EP1147785A2 Therapeutic light source
10/24/2001	EP1147413A2 Growth differentiation factor inhibitors and uses therefor
10/24/2001	EP1147202A2 Plasminogen kringle 4 region fragments and methods of use
10/24/2001	EP1147191A1 Transcriptional regulation of the human beta3-adrenergic receptor gene
10/24/2001	EP1147167A1 Method for obtaining an oil that is rich in hydroxyoctadecadienoic fatty acids (hode) or the esters thereof from a mixture containing linoleic acid or the esters thereof
10/24/2001	EP1147138A1 Hydrophilic ampholytic polymer
10/24/2001	EP1147136A1 DNA ENCODING A MAMMALIAN RECEPTOR (fb41a) AND USES THEREOF
10/24/2001	EP1147119A1 2,3-o-isoproylidene derivatives of monosaccharides as cell adhesion inhibitors
10/24/2001	EP1147110A1 Pyrazino(aza)indole derivatives
10/24/2001	EP1147107A1 Novel angiogenesis inhibitors
10/24/2001	EP1147104A1 Aromatic heterocyclic compounds as antiinflammatory agents
10/24/2001	EP1147102A2 Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
10/24/2001	EP1147095A1 2, 3, 4, 5-tetrahydro-1h-[1, 4] benzodiazepine-3-hydroxamic acids as matrix metalloproteinase inhibitors
10/24/2001	EP1147094A1 Non-peptide glp-1 agonists
10/24/2001	EP1147092A1 Substituted imidazoles, their preparation and use
10/24/2001	EP1147091A2 Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by vla-4
10/24/2001	EP1147078A1 Acetylenic (beta)-sulfonamido and phosphinic acid amide hydroxamic acid tace inhibitors
10/24/2001	EP1146902A1 Treatment of autommune diseases by an agonistic cd40-binding protein
10/24/2001	EP1146896A2 Monodisperse hexameric acylated insulin analog formulations
10/24/2001	EP1146888A2 Specific therapeutic interventions obtained by interference with redistribution and/or targetting
10/24/2001	EP1146883A1 Modulation of immune response by ribavirin
10/24/2001	EP1146845A2 Compressed lecithin preparations
10/24/2001	EP1035824A4 A process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
10/24/2001	EP0848704B1 Form iii crystalline [r-(r,r)]-2-(4-fluorophenyl)-beta-delta-dihydroxy-5-(1-methyl-ethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
10/24/2001	EP0820433B1 O-malonyltyrosyl compounds, o-malonyltyrosyl compound-containing peptides, and uses thereof
10/24/2001	EP0648212B1 Benzoxazole and benzothiazole derivatives as pharmaceutical
10/24/2001	CN1319133A Short peptides which selectively modulate activity of protein kinases
10/24/2001	CN1319097A Benzoxazine and benzothiazine derivatives and their use in medicines
10/24/2001	CN1319094A Imidazolyl derivatives
10/24/2001	CN1319093A Aminoalkyl-3,4-dihydroquindine derivates as No-synthase inhibitors
10/24/2001	CN1319088A Arylsulfonanilide ureas
10/24/2001	CN1319016A Process for preparation of oral pharmaceutical compositions comprising biphosphonates
10/24/2001	CN1319015A Compositions containing diphosphonic acids
10/24/2001	CN1319012A Method for treating diabetes employing ap2 inhibitor and combination
10/24/2001	CN1318640A Multi-element making up ionic wine and its production process
10/24/2001	CN1318392A Beriberi treating ointment
10/24/2001	CN1318382A Nutrient agent and its application
10/24/2001	CN1318373A Application of Breviscapine in preparing medicine
10/24/2001	CN1318371A New use of flavone
10/24/2001	CN1318370A Application of fumaric acid in preparing medicine
10/24/2001	CN1073557C Vitamin-D amide derivatives
10/23/2001	US6307080 Water-soluble zinc pyruvates or their hydrates, method for the product ion thereof and their use
10/23/2001	US6306911 Enzyme inhibitors

1 ... 1035 1036 1037 1038 1039 1040 1041 1042 1043 1044 1045 1046 1047 1048 1049 1050 1051 1052 1053 1054 1055 ... 1298